跳至主要内容
临床试验/NL-OMON30092
NL-OMON30092尚未招募不适用

Pharmacogenetic testing in the clinical setting: is screening for TPMT genotype a cost-effective treatment strategy? The first prospective randomized controlled trial within the Dutch health care system. - cost-effectiveness of TPMT pharmacogenetic testing

Zorgonderzoek Nederland (ZON)0 个研究点目标入组 1,000 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • · Age 18 or older
  • · Diagnosis of a form of IBD
  • · Patient is started on azathioprine treatment
  • · Patient giving informed consent

排除标准

  • · Previous treatment with azathioprine
  • · Co-prescription of allopurinol (this treatment blocks xanthine oxidase, an enzyme
  • important for azathioprine metabolism)
  • · Baseline leukocyte count less then 3x10^9 per litre
  • · Reduced baseline liver function
  • · Reduced renal function at baseline
  • · Use of TPMT phenotype test to guide prescription
  • · Pregnancy or breastfeeding

研究者

发起方
Zorgonderzoek Nederland (ZON)

相似试验

Pharmacogenetic testing in the clinical setting: is... | 临床试验